TTM
−$0.83
YoY change
-26.9%
5Y CAGR
—
Peak year (2025)
−$0.87
Latest annual
−$0.87
EPS (Diluted) history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: −$0.87
EPS (Diluted) growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: -26.9%
EPS (Diluted) history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | −$0.87 | -26.9% | +$0.32 | ||
| 2024 | −$1.19 | +10.2% | −$0.11 | ||
| 2023 | −$1.08 | -12.2% | +$0.15 | ||
| 2022 | −$1.23 | +30.9% | −$0.29 | ||
| 2021 | −$0.94 | -42.0% | +$0.68 | ||
| 2020 | −$1.62 | +3.2% | −$0.05 | ||
| 2019 | −$1.57 | — | — |
- 2025−$0.87-26.9%
- 2024−$1.19+10.2%
- 2023−$1.08-12.2%
- 2022−$1.23+30.9%
- 2021−$0.94-42.0%
- 2020−$1.62+3.2%
- 2019−$1.57—
EPS (Diluted) values are taken from Tango Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's current diluted EPS (TTM) is −$0.83. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Tango Therapeutics (TNGX) most recent annual diluted EPS stands at −$0.87 (2025) – declined 26.9% year-over-year.
The record annual diluted EPS stands at −$0.87, reached in 2025; the historical low of −$1.62 was recorded in 2020.
Tango Therapeutics EPS (Diluted) by Year
Tango Therapeutics EPS (Diluted) 2025: −$0.87
In 2025, Tango Therapeutics reported diluted EPS of −$0.87, declined 26.9% below 2024. This figure represents the highest annual value in the available history.
Tango Therapeutics EPS (Diluted) 2024: −$1.19
Tango Therapeutics diluted EPS in 2024 was −$1.19, grew 10.2% from 2023.
Tango Therapeutics EPS (Diluted) 2023: −$1.08
2023's diluted EPS for Tango Therapeutics came in at −$1.08, declined 12.2% below 2022.
Tango Therapeutics EPS (Diluted) 2022: −$1.23
Tango Therapeutics posted diluted EPS of −$1.23 in 2022, surged 30.9% from 2021.
Tango Therapeutics EPS (Diluted) 2021: −$0.94
Tango Therapeutics diluted EPS in 2021 was −$0.94.
See more financial history for Tango Therapeutics (TNGX). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation